In the last trading session, 3.84 million GT Biopharma Inc (NASDAQ:GTBP) shares changed hands as the company’s beta touched 0.63. With the company’s per share price at $2.39 changed hands at -$0.26 or -9.81% during last session, the market valuation stood at $5.34M. GTBP’s last price was a discount, traded about -346.03% off its 52-week high of $10.66. The share price had its 52-week low at $1.72, which suggests the last value was 28.03% up since then. When we look at GT Biopharma Inc’s average trading volume, we note the 10-day average is 81540.0 shares, with the 3-month average coming to 382.41K.
Analysts gave the GT Biopharma Inc (GTBP) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended GTBP as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. GT Biopharma Inc’s EPS for the current quarter is expected to be 0.
GT Biopharma Inc (NASDAQ:GTBP) trade information
Instantly GTBP was in red as seen at the end of in last trading. With action -20.33%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -21.64%, with the 5-day performance at -20.33% in the red. However, in the 30-day time frame, GT Biopharma Inc (NASDAQ:GTBP) is -21.42% down. Looking at the short shares, we see there were 17725.0 shares sold at short interest cover period of 0.71 days.
GT Biopharma Inc (GTBP) estimates and forecasts
Data shows that the GT Biopharma Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -18.43% over the past 6 months, a -20.39% in annual growth rate that is considerably lower than the industry average of 16.40%.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 70.75%.
GTBP Dividends
GT Biopharma Inc is expected to release its next quarterly earnings report in February.
GT Biopharma Inc (NASDAQ:GTBP)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 12.15% of GT Biopharma Inc shares while 67.52% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 76.85%.
Among Mutual Funds, the top two as of Nov 30, 2024 were Fidelity Extended Market Index Fund and Vanguard Extended Market Index Fund . With 11.13 shares estimated at $26595.0 under it, the former controlled 0.50% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 0.47% of the shares, roughly 10.5 shares worth around $25104.0.
